1. Home
  2. KNSA vs NTST Comparison

KNSA vs NTST Comparison

Compare KNSA & NTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • NTST
  • Stock Information
  • Founded
  • KNSA 2015
  • NTST 2019
  • Country
  • KNSA United Kingdom
  • NTST United States
  • Employees
  • KNSA N/A
  • NTST N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • NTST Real Estate Investment Trusts
  • Sector
  • KNSA Health Care
  • NTST Real Estate
  • Exchange
  • KNSA Nasdaq
  • NTST Nasdaq
  • Market Cap
  • KNSA 1.5B
  • NTST 1.2B
  • IPO Year
  • KNSA 2018
  • NTST 2020
  • Fundamental
  • Price
  • KNSA $20.21
  • NTST $16.50
  • Analyst Decision
  • KNSA Strong Buy
  • NTST Strong Buy
  • Analyst Count
  • KNSA 6
  • NTST 8
  • Target Price
  • KNSA $37.17
  • NTST $18.03
  • AVG Volume (30 Days)
  • KNSA 638.0K
  • NTST 1.1M
  • Earning Date
  • KNSA 04-29-2025
  • NTST 04-28-2025
  • Dividend Yield
  • KNSA N/A
  • NTST 5.10%
  • EPS Growth
  • KNSA N/A
  • NTST N/A
  • EPS
  • KNSA N/A
  • NTST N/A
  • Revenue
  • KNSA $423,239,000.00
  • NTST $162,784,000.00
  • Revenue This Year
  • KNSA $37.21
  • NTST $10.52
  • Revenue Next Year
  • KNSA $2.58
  • NTST $7.83
  • P/E Ratio
  • KNSA N/A
  • NTST N/A
  • Revenue Growth
  • KNSA 56.60
  • NTST 23.41
  • 52 Week Low
  • KNSA $16.56
  • NTST $13.42
  • 52 Week High
  • KNSA $28.15
  • NTST $18.10
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 44.56
  • NTST 67.78
  • Support Level
  • KNSA $18.26
  • NTST $14.74
  • Resistance Level
  • KNSA $21.24
  • NTST $15.53
  • Average True Range (ATR)
  • KNSA 1.12
  • NTST 0.61
  • MACD
  • KNSA -0.12
  • NTST 0.09
  • Stochastic Oscillator
  • KNSA 44.43
  • NTST 96.53

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About NTST NetSTREIT Corp.

Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.

Share on Social Networks: